-
Mashup Score: 3
Polatuzumab vedotin plus R-CHP improved PFS and DFS vs R-CHOP at 5 years in previously untreated patients with diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3TAK-007 Shows Favorable Safety, Early Efficacy Data in R/R B-Cell Non-Hodgkin Lymphoma - 4 day(s) ago
A phase 2 study demonstrated that TAK-007 had a favorable safety profile with early efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
TAK-007 Shows Favorable Safety, Early Efficacy Data in R/R B-Cell Non-Hodgkin Lymphoma @ASH_hematology #ASH24 #lymsm https://t.co/B79A0AAmWe
-
-
Mashup Score: 2Addition of ASCT to Ibrutinib Plus Rituximab Does Not Confer Benefit in Lower-Risk, Younger MCL - 5 day(s) ago
Martin Dreyling, MD, PhD, discusses the role of ASCT with or without an ibrutinib-based regimen in younger patients with mantle cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
The addition of ASCT to ibrutinib/rituximab and chemotherapy did not produce efficacy or safety benefits compared with ibrutinib plus rituximab and chemotherapy without ASCT in patients with MCL younger than 65 years of age. @ASH_hematology #ASH24 #lymsm https://t.co/D68NjnAIkG https://t.co/B8HIEoKWwb
-
-
Mashup Score: 3Rapcabtagene Autoleucel May Be Safe and Efficacious in R/R DLBCL - 10 day(s) ago
Peter Riedell, MD, details the safety and efficacy of rapcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Rapcabtagene Autoleucel May Be Safe and Efficacious in R/R DLBCL @ASH_hematology #ASH24 #lymsm https://t.co/W3Re3mmsWd
-
-
Mashup Score: 3ASH 2024: Changing the Treatment Landscape in Lymphoma - 2 month(s) ago
Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Advances in MCL and FL from #ASH24. With @SehnLaurie of @BCCancer, @timfenske of @MedicalCollege, @poh_christina of @fredhutch & @UW, Dr Sunita Nasta of @PennCancer, @LymphClinician of @cityofhope, @DrMatasar of @RutgersCancer, and more. #lymsm https://t.co/SrtEqdxDTQ
-
-
Mashup Score: 2
In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction. Presented at #ASH24 by @timfenske from @MedicalCollege. #lymsm https://t.co/3LOBwc5LP0 https://t.co/O5yn1rF7g6
-
-
Mashup Score: 79Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial - 2 month(s) ago
Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile.
Source: www.thelancet.comCategories: General Medicine News, Partners & KOLsTweet-
Impressive results for CD19 directed ADC loncastuximab tesirine in follicular lymphoma - why was it not developed in FL sooner?! Now published in @TheLancetHaem https://t.co/dx1rFSxG1M (almost all patients CAR T naive) #ASH24 #lymsm https://t.co/wusKCNukF7
-
-
Mashup Score: 0Tafasitamab Triplet: A New Standard for Rel/Ref Follicular Lymphoma? - 2 month(s) ago
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma. Presented at #ASH24 by @SehnLaurie from @BCCancer and @UBC. #lymsm https://t.co/MYOofBEYHm https://t.co/QQDEyeou0J
-
-
Mashup Score: 1Lenalidomide Improves Upon Durvalumab in CTCL - 2 month(s) ago
Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Lenalidomide improved upon the efficacy of durvalumab in patients with refractory or advanced CTCL in a phase 1/2 trial. Presented at #ASH24 by Dr Christiane Querfeld from @cityofhope. #lymsm https://t.co/ZYYnZpelGD https://t.co/y6OYFq23zi
-
-
Mashup Score: 0Paper: A Healthcare Utilization Model Comparing Time Toxicity between Glofitamab and Epcoritamab - 2 month(s) ago
Program: Oral and Poster Abstracts Session: 902. Health Services and Quality Improvement: Lymphoid Malignancies: Poster II Hematology Disease Topics & Pathways: Research, Lymphomas, Non-Hodgkin lymphoma, Bispecific Antibody Therapy, Clinical Research, Health outcomes research, Diseases, Indolent lymphoma, Real-world evidence, Treatment Considerations, Biological therapies, Lymphoid Malignancies Pallawi Torka, MD 1, Anthony Masaquel 2 *, Lourenia Cassoli 2 *, David Fox 2 *, Arliene Ravelo 2 * and Ajay
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Many thanks to Dr. @PallawiTorkaMD for your collaboration and to Dr. @guptaarjun90 for pioneering time toxicity as a patient-centered outcome! #ASH24 #lymsm Abstract link: https://t.co/4QLhfdOEev https://t.co/ScpdoKnggJ
-
Pola-R-CHP Generates Long-Term PFS and DFS Advantages vs R-CHOP in Untreated DLBCL @ASH_hematology #ASH24 #lymsm https://t.co/UCsXK1gTU4